Rizatriptan benzoate and Visual field defect - a phase IV clinical study of FDA data

Summary:

Visual field defect is reported as a side effect among people who take Rizatriptan benzoate (rizatriptan benzoate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Dilaudid, and have Depression.

The phase IV clinical study analyzes which people have Visual field defect when taking Rizatriptan benzoate. It is created by eHealthMe based on reports of 1,704 people who have side effects when taking Rizatriptan benzoate from the FDA, and is updated regularly.

What is Rizatriptan benzoate?

Rizatriptan benzoate has active ingredients of rizatriptan benzoate. It is often used in migraine. eHealthMe is studying from 1,886 Rizatriptan benzoate users. Check the latest studies of Rizatriptan benzoate.

What is Visual field defect?

Visual field defect is found to be associated with 766 drugs and 1,038 conditions by eHealthMe. Check the latest studies of Visual field defect.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

1,704 people reported to have side effects when taking Rizatriptan benzoate.
Among them, 16 people (0.94%) have Visual field defect.

Could Rizatriptan benzoate cause Visual field defect?

Among these 16 people:

How long have people been on Rizatriptan benzoate when they have Visual field defect? *

What is the gender of people who have Visual field defect when taking Rizatriptan benzoate? *

female: 92.31 %
male: 7.69 %

What is the age of people who have Visual field defect when taking Rizatriptan benzoate? *

What are other drugs people take besides Rizatriptan benzoate? *

Dilaudid: 15 people, 93.75%
Propranolol Hydrochloride: 10 people, 62.50%
Elavil: 10 people, 62.50%
Aimovig: 10 people, 62.50%
Topiramate: 7 people, 43.75%
Diclofenac: 7 people, 43.75%
Acetaminophen: 7 people, 43.75%
Diclofenac Sodium: 6 people, 37.50%
Allopurinol: 5 people, 31.25%
Topamax: 3 people, 18.75%

What are other side effects people have besides Visual field defect? *

Speech Impairment (Adult) (inability to speak (adult)): 15 people, 93.75%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 15 people, 93.75%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 14 people, 87.50%
Food Intolerance (inability to have food): 7 people, 43.75%
Drug Ineffective: 6 people, 37.50%

What are the existing conditions these people have? *

Depression: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Rizatriptan benzoate and have Visual field defect?

- Check whether Visual field defect is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rizatriptan benzoate:

Rizatriptan benzoate (1,886 reports)

Browse all side effects of Rizatriptan benzoate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual field defect:

Visual field defect (766 drugs)

Browse all the conditions that are associated with Visual field defect:

Visual field defect (1,038 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rizatriptan benzoate (the active ingredients of Rizatriptan benzoate) and Rizatriptan benzoate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.